IRadimed (IRMD) Earnings Analysis

IRadimed (IRMD) next reports earnings on 2026-07-30, consensus EPS 0.44 USD. Last quarter (2026-05-01) it beat with EPS 0.49 USD vs 0.45 USD est (+8.9%). It has beaten estimates in 4/7 recent quarters (57%). Trailing P/E 50.58.

Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades

When does IRMD next report earnings?

Next earnings date2026-07-30
Consensus EPS estimate0.44 USD
Revenue estimate0.02B

IRMD earnings history — beats and misses

Quarter (report date)EPS actualEPS est.SurpriseResult
2026-05-010.49 USD0.45 USD+8.9%Beat
2025-11-030.47 USD0.48 USD-2.1%Miss
2025-08-010.49 USD0.45 USD+8.9%Beat
2025-05-050.42 USD0.43 USD-2.3%Miss
2025-02-130.44 USD0.45 USD-2.2%Miss
2024-10-310.43 USD0.39 USD+10.3%Beat
2024-08-010.42 USD0.37 USD+13.5%Beat

Beat rate: 4/7 (57%) over reported quarters with consensus data.

IRMD valuation and analyst view

Trailing P/E50.58
Trailing EPS1.847 USD
Price / book12.21
Dividend yield1.32%
Market cap1.21B
Analyst consensusBuy (2 buy / 0 hold / 0 sell)
Avg price target105.6 USD

Related research pages

Frequently asked questions

When is IRadimed (IRMD)'s next earnings date?

IRadimed is next scheduled to report on 2026-07-30, with a consensus EPS estimate of 0.44 USD and revenue estimate of 0.02B.

Did IRMD beat earnings last quarter?

In its 2026-05-01 report, IRMD posted EPS of 0.49 USD versus a 0.45 USD estimate — a beat of 8.9%.

What is IRMD's earnings track record?

Over the last 7 reported quarters with consensus data, IRMD beat estimates 4 times (57%).

What is IRMD's current P/E ratio and EPS?

IRMD trades at a trailing P/E of 50.58 on trailing EPS of 1.847032230305875 USD.

What do analysts rate IRMD?

Analyst consensus is "Buy" across 2 ratings (0 strong buy, 2 buy, 0 hold, 0 sell, 0 strong sell). Average 12-month price target: 105.6 USD.